A securities class action lawsuit has been filed on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered losses between January 19, 2026 and March 24, 2026. The Rosen Law Firm filed the case on March 26, 2026, alleging that company executives made false and misleading statements about Anktiva, an immunotherapy drug for non-muscle invasive bladder cancer. The lawsuit names the company’s Executive Chairman and Global Scientific and Medical Officer as defendants for allegedly overstating the drug’s capabilities and making claims that have not been substantiated—particularly the assertion that Anktiva would allow all patients treated with it to be cancer-free for the long term, and the characterization of the drug as a “cancer vaccine.” If you purchased ImmunityBio stock during this period and experienced losses following the FDA’s warning letter about these claims on March 24, 2026, you may be eligible to participate in this class action.
The FDA’s March 24, 2026 warning letter served as a catalyst for the stock price decline that prompted the legal action. The warning letter challenged ImmunityBio’s promotional claims about Anktiva, which effectively validated investor concerns about the statements made by company leadership. Investors who bought stock during this window are now able to seek recovery for their losses, with a lead plaintiff deadline of May 26, 2026. Understanding this lawsuit is critical if you held ImmunityBio stock during this period, as there are specific deadlines and steps you must follow to protect your legal rights.
Table of Contents
- What Was ImmunityBio Promoting About Anktiva Before the FDA Warning?
- How Did the FDA Warning Letter Expose the False Claims?
- Who Are the Defendants in This Class Action?
- What Is the Lead Plaintiff Deadline and What Does It Mean?
- What Is the Class Period and Who Qualifies?
- The Law Firms and Their Experience
- What Happens After the Lead Plaintiff Deadline?
What Was ImmunityBio Promoting About Anktiva Before the FDA Warning?
immunitybio made specific claims about Anktiva’s effectiveness in treating non-muscle invasive bladder cancer (NMIBC) that the company later admitted were not supported by clinical evidence. The most problematic claim was the statement that “Anktiva will allow all NMIBC patients treated with Anktiva to be cancer-free for the long term.” This broad assertion implied a level of efficacy that had not been demonstrated in clinical trials, misleading investors about the drug’s real-world performance potential. By characterizing Anktiva as a “cancer vaccine” rather than as an immunotherapy drug, ImmunityBio further overstated what the drug was designed to do and created unrealistic expectations among investors about its market opportunity and regulatory pathway.
The distinction between how a drug is actually classified and how it’s marketed matters enormously for investors. When a company calls a treatment a “vaccine” rather than identifying it as an immunotherapy, it triggers different regulatory requirements, market expectations, and investor perceptions about the company’s understanding of its own product. In this case, the FDA warning letter essentially told the company to stop making these claims—a direct contradiction of what executives had been saying to investors and the public. For example, if you heard company leadership present Anktiva as a broadly applicable solution for cancer patients before March 24, 2026, you were receiving information that the FDA later found to be misleading.
How Did the FDA Warning Letter Expose the False Claims?
The FDA’s warning letter issued on March 24, 2026 formally documented that ImmunityBio’s claims about Anktiva were not substantiated by clinical data. The warning letter is a significant regulatory action that signals the FDA has found violations in how the company is promoting the drug. Unlike a simple rejection of a drug application, a warning letter is a serious enforcement action that typically triggers investor concerns and often results in stock price declines. In this case, the warning letter’s issuance on March 24, 2026 appears to have been the catalyst that prompted the 2-month “class period” from January 19 to March 24, 2026—essentially marking the window during which investors were misled before regulatory authorities intervened.
However, it’s important to understand that a warning letter doesn’t automatically mean the drug is dangerous or ineffective. The FDA warning was specifically about how ImmunityBio was promoting the drug to investors and the public, not necessarily about the drug’s actual performance in clinical settings. The problem was one of marketing claims, not clinical safety. Nevertheless, the warning letter did damage investor confidence because it raised questions about the company’s credibility and internal controls. If you purchased stock believing the company’s representations about Anktiva’s broad applicability to cancer patients, the warning letter revealed that you had been given overstated information by company leadership.
Who Are the Defendants in This Class Action?
The lawsuit names ImmunityBio, Inc. and two key executives as defendants: the company’s Executive Chairman and the Global Scientific and Medical Officer. These individuals were responsible for the statements made about Anktiva’s capabilities, and the lawsuit alleges they either knew the claims were false or acted with reckless disregard for the truth. In securities class actions involving pharmaceutical companies, identifying which executives made specific misleading statements is crucial because it establishes who bears responsibility for the false claims.
The involvement of the Global Scientific and Medical Officer is particularly significant because this person would typically be expected to ensure that scientific claims about drug efficacy are accurate. Securities law holds executives personally accountable for statements they make about their companies, especially regarding drug efficacy and regulatory matters. If you can show that you relied on specific statements made by these executives when deciding to buy or hold ImmunityBio stock, you strengthen your claim to be part of the class action. Many investors discover years later that public statements they relied on were later proven to be misleading—in this case, the timeline was much shorter (just two months), making it relatively clear which statements were false.
What Is the Lead Plaintiff Deadline and What Does It Mean?
The lead plaintiff deadline for this class action is May 26, 2026, which gives eligible investors exactly two months from the filing date (March 26, 2026) to request appointment as lead plaintiff. A lead plaintiff is the investor or group of investors who officially represent the entire class in the lawsuit and work most closely with the attorneys. Being appointed lead plaintiff comes with certain responsibilities and potential involvement in settlement negotiations, but it also provides input into how the lawsuit is conducted. If you are an ImmunityBio shareholder who lost money during the class period and believe you are a significant investor, you can submit a request to be considered for lead plaintiff status.
However, it’s important to understand that even if you don’t become lead plaintiff, you are still eligible to participate in the class action and potentially recover losses. The lead plaintiff deadline is specifically for those who want to take a leadership role; regular class members don’t have to do anything by this date to remain eligible. If you lost a substantial amount of money on ImmunityBio stock (generally more than $100,000), you might consider whether becoming lead plaintiff makes sense for your situation. The Rosen Law Firm and Robbins Geller Rudman & Dowd LLP, the law firms handling this case, can provide guidance on the lead plaintiff process and whether it’s appropriate for your level of losses.
What Is the Class Period and Who Qualifies?
The class period runs from January 19, 2026 through March 24, 2026—a two-month window during which ImmunityBio made false claims about Anktiva and investors traded the stock at artificially inflated prices. To be eligible for this class action, you must have purchased ImmunityBio stock (NASDAQ: IBRX) during this period and experienced losses. The start date of January 19, 2026 marks when the company apparently began making the false statements about Anktiva, while March 24, 2026 marks when the FDA warning letter exposed those claims to the public.
If you bought ImmunityBio stock at any point between these dates and still held it (or sold it at a loss) after the FDA warning became public, you likely qualify for the class. A critical limitation to understand: this is a securities class action for investors, not a product liability case for patients who actually used Anktiva. If you or a family member was harmed by Anktiva directly, you may have other legal options, but this particular lawsuit is specifically about financial losses resulting from stock price decline. Additionally, the lawsuit only covers stock purchased during the specific class period—if you bought ImmunityBio stock before January 19, 2026 or after March 24, 2026, you are not eligible for this particular class action (though other legal claims might be available depending on your situation).
The Law Firms and Their Experience
The Rosen Law Firm and Robbins Geller Rudman & Dowd LLP are both experienced in securities class actions and have handled numerous pharmaceutical company lawsuits over the years. Robbins Geller is particularly well-known for securities litigation involving misstatements about drug efficacy and regulatory matters. Having two established law firms involved in the case provides redundancy and increased legal firepower, which generally benefits class members by ensuring thorough investigation and aggressive representation.
These firms typically work on a contingency basis, meaning they only collect fees if the class recovers money—either through settlement or trial verdict. in securities class actions, attorney fees are typically paid from any recovery (usually 25-30% of the settlement or judgment), and class members don’t pay out-of-pocket legal fees. This structure aligns the attorneys’ interests with the class members’ interests: they only make money if you recover money. You should verify information about the lawsuit through the official court documents and the law firms’ websites rather than relying on third-party sites, as some websites misrepresent class action details or attempt to redirect potential claimants.
What Happens After the Lead Plaintiff Deadline?
After May 26, 2026, the lead plaintiff (or plaintiffs) will be appointed by the court, and the legal process will move forward toward either settlement negotiations or trial. The next phase typically involves discovery, where both sides exchange documents and information to build their cases. For a pharmaceutical securities case like this, discovery will likely include emails and communications from ImmunityBio executives discussing Anktiva’s efficacy, internal clinical data, and communications with the FDA. This process can take months or even years, depending on the complexity of the case.
Most securities class actions settle before reaching trial, often 18-36 months after the initial filing. Settlement discussions frequently accelerate once key facts have been established through discovery and both sides understand the strength of each party’s position. The final settlement amount and terms will depend on factors including the strength of the evidence, the defendants’ willingness to pay, and the size of the class. If you’re eligible for this class action, you don’t need to do anything immediately except be aware of the May 26, 2026 lead plaintiff deadline if you want to pursue that role—simply being aware that you qualify is sufficient to preserve your rights at this stage.